Halving your position is likely a smart move, before a reverse split or increase in outstanding shares halves your invested dollars first. They are burning through about $80 Million per year with no substantial profits in sight. That will only be back filled buy printing and issuing new shares which means more dilution of your investment and a potentially much lower share price. Even with an MHRA approval, they still need NICE approval for NHS reimbursement and still have to run 2 pediatric trials. Without NICE approval, it will be the same situation as the last 11 years of C Care, which has not generated any revenue to speak of over the entire 11 years. The sweet spot for NHS reimbursement approval is about $35,000.00. DCVax is $150 - $200 K. Very low probability that they will pay all of that money for a questionable trial with only a couple of month increased OS (which is still questionable) - on TOP of current surgical removal and SOC chemo and radiation.
These are just my opinions , I do not give investment advice one way or the other. I hope you make the right decision for yourself. GL
Market Data 
Markets 
